more info and exposure, page-5

http://www.biocentury.com/biotech-p...ptional-responders-for-antibodies-targets-a03

This private company Oncoresponse was somehow able to raise 12M in an A series round. All they have is a
platform technology that screens antibodies made by the immune system and identify those with exceptional reactivity to cancer immunotherapy - specifically B-cells

"The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, to interrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer."

http://www.oncoresponseinc.com/